Analysis on the development depth of the market of antitumor drugs in Guangdong Province

Source: minenet 2013-9-24 according to the global cancer epidemic statistics released by the World Health Organization, in 2008, there were about 12.7 million new cancer cases in the world, of which 7.6 million died It is expected that cancer death will continue to increase in the world, and by 2030, 12 million people will die of cancer, and cancer has become the first major cause of death in developed countries According to the 2012 China cancer registration annual report released by the National Cancer Registration Center in 2013, there are about 3.12 million new cancer cases every year, with an average of 8550 people per day Six people are diagnosed with cancer every minute in the country On July 3, 2013, Guangdong Province published the catalogue of essential drugs supplement varieties (2013 version) The anti-tumor drugs included in the catalogue include pirarubicin, vinorelbine and topotecan, with 3 dosage forms and multiple specifications, involving multiple enterprises Pirarubicin belongs to alkylating agents, which are the first cytotoxic drugs The mechanism of its action on cancer cells is mainly to enter the cells, rapidly distribute in the nucleus, inhibit DNA polymerase α and β, and hinder the synthesis of nucleic acid The drug embeds the double helix of DNA, which makes the tumor cells stop at G2 stage, and can not go to the cell division stage, leading to the death of tumor cells Pirarubicin is mainly used in malignant lymphoma, acute leukemia, breast cancer, urothelial cancer (bladder cancer and ureteral cancer), ovarian cancer, cervical cancer, head and neck cancer and gastric cancer The competition pattern of pirarubicin (Figure 1) shows that pirarubicin has increased slowly in recent years At present, only Zhejiang Haizheng Pharmaceutical Co., Ltd and Shenzhen Wanle Pharmaceutical Co., Ltd produce pirarubicin in China Pirarubicin is the main product of Shenzhen Wanle pharmaceutical industry Half of the company's annual revenue comes from the sales of pirarubicin From the perspective of enterprise competition, in recent years, Shenzhen Wanle Pharmaceutical Co., Ltd ranked first with more than 90% market share, becoming the leading enterprise of this kind of drugs Fig 1: Sales of pirarubicin in the past five years Vinorelbine is a plant classified antitumor drug Its main function is to combine with tubulin, so as to prevent the formation of microtubules in the process of mitosis When its concentration is more than 12 nmol, it can block the G2-M phase of cells Vinorelbine is mainly used in non-small cell lung cancer, breast cancer, ovarian cancer, lymphoma, etc Because it is mainly excreted by biliary tract, it can also be used in patients with renal dysfunction Vinorelbine, which was selected into the supplementary catalogue of basic drugs in Guangdong Province, has the most enterprises involved From the perspective of urban competition pattern, in recent years, Shanghai has the largest number of such drugs, accounting for more than 20% of the market share As a representative city of Guangdong Province, the sales volume of Changchun Ruibin is increasing year by year, and it has become the second largest city in 2012 from the sixth in 2008 Topotecan hydrochloride is transformed from camptothecin Camptothecin has a good effect on gastrointestinal cancer and head and neck cancer Topotecan hydrochloride is mainly prepared from camptothecin, a natural product, by hydrogenation, reduction and oxidation to produce 10 hydroxycamptothecin, which is then reacted with bis (dimethylamino) methane Topotecan hydrochloride was first researched and developed by SmithKline Beecham company in the United Kingdom It was listed in the United States in 1996 and then entered the Chinese market It can be used in the treatment of all solid tumors It is the best drug to treat ovarian cancer It can also be used in the treatment of breast cancer, rectal cancer, colon cancer, acute and chronic leukopenia In the past, topotecan hydrochloride has been marketed in China as an intravenous drug In 2007, Nanjing ruinian best Pharmaceutical Co., Ltd exclusively launched a capsule formulation, which is more convenient to take and carry, and increases the compliance of patients There were 26 kinds of antineoplastic drugs in the national basic drug list earlier In addition to the supplementary varieties of Guangdong Province, there were 29 kinds of antineoplastic drugs in the actual executive basic drug list in Guangdong Province The market potential of this kind of drugs is huge At present, there are many manufacturers involved and the competition is very fierce It needs to continue to observe who can stand out in the end.